0000000000557732

AUTHOR

Alessandra Rubagotti

0000-0002-4009-8829

showing 3 related works from this author

Prognostic value of nuclear matrix protein expression in localized prostate cancer.

2012

The aim of the study was to correlate nuclear matrix (NM) protein expression profiles with the risk of PSA progression or death in early prostate cancer (PCa).High-resolution two-dimensional gel electrophoresis (2D-PAGE) was used to identify tumor-associated NM proteins in the PCa specimens obtained from 94 patients. The association between the expression of each protein and the probability of PSA progression or death was studied through univariate analysis. Unsupervised hierarchical clustering analysis was then used to generate patient clusters showing comparable outcomes by including the proteins that were predictive at univariate analysis. PSA-free and overall survival curves relative to…

OncologyPCA3MaleCancer Researchmedicine.medical_specialtyPrognosiPSA progressionValue (computer science)Kaplan-Meier EstimateNuclear matrix proteins; Prognosis Prostate cancer; PSA progressionurologic and male genital diseasesNuclear Matrix-Associated ProteinFollow-Up StudieProstate cancerNuclear Matrix-Associated ProteinsInternal medicinemedicineCluster AnalysisHumansElectrophoresis Gel Two-DimensionalNuclear matrix proteinMultivariate AnalysiProportional Hazards ModelsNuclear matrix proteinsHematologyCluster AnalysiProstate cancerProportional hazards modelbusiness.industryProstatic NeoplasmsPSA PROGRESSIONGeneral MedicineProstate-Specific AntigenNuclear matrixmedicine.diseasePrognosisProstate-specific antigenOncologyMultivariate AnalysisDisease ProgressionProportional Hazards ModelbusinessFollow-Up StudiesHuman
researchProduct

Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer

2015

Aim To evaluate the optimal time interval from definitive surgery to commencing chemotherapy in early breast cancer (EBC). Patients and methods The relationship between time to initiation of adjuvant chemotherapy (TTC), calculated in weeks, and disease-free (DFS) or overall survival (OS), was assessed in 921 EBC patients with rapidly proliferating tumours (thymidine labelling index >3% or G3 or Ki67 >20%), randomised in a phase III clinical trial (NCT01031030) to receive chemotherapy with or without anthracyclines (epirubicin → cyclophosphamide, methotrexate and fluorouracil (CMF) versus CMF → epirubicin versus CMF). DFS, OS and 95% confidence intervals (95% confidence interval (CI)) …

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentKaplan-Meier EstimateRisk FactorsAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyMultivariate AnalysiAdjuvantMastectomyMedicine (all)Hazard ratioEarly breast cancerMiddle AgedTreatment OutcomeItalyOncologyChemotherapy AdjuvantFluorouracilDisease ProgressionFemaleBreast NeoplasmMastectomyHumanmedicine.drugRapidly proliferating tumourAdultmedicine.medical_specialtyTime FactorBreast NeoplasmsDisease-Free SurvivalTime-to-TreatmentAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Female; Humans; Italy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Cell Proliferation; Mastectomy; Time-to-Treatment; Cancer Research; Oncology; Medicine (all)Internal medicinemedicineChemotherapyHumansAgedNeoplasm StagingProportional Hazards ModelsCell ProliferationChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryProportional hazards modelRisk FactorAdjuvant chemotherapy; Early breast cancer; Rapidly proliferating tumour; Time to initiation of adjuvant chemotherapy; Cancer Research; OncologyConfidence intervalSurgeryAdjuvant chemotherapyProspective StudieTime to initiation of adjuvant chemotherapyMultivariate AnalysisProportional Hazards ModelMethotrexateNeoplasm Gradingbusiness
researchProduct

Endocrine therapy of breast cancer. The experience of the Italian Cooperative Group for Chemohormonal Therapy of Early Breast Cancer (GROCTA).

1993

Oncologymedicine.medical_specialtybusiness.industryGeneral NeuroscienceEndocrine therapyBreast Neoplasmsmedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyPostmenopauseTamoxifenBreast cancerHistory and Philosophy of SciencePremenopauseReceptors EstrogenChemotherapy AdjuvantRecurrenceInternal medicinemedicineCooperative groupHumansFemalebusinessEarly breast cancerProbability
researchProduct